Santhera Pharmaceuticals

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company founded in 2004, dedicated to developing medicines for patients with rare neuromuscular diseases. The company's flagship product, AGAMREE® (vamorolone), offers a novel mode of action as an alternative to standard corticosteroids for the treatment of Duchenne muscular dystrophy (DMD). It has received approvals from regulatory bodies including the FDA, EMA, and MHRA. Santhera has strategically out-licensed rights for AGAMREE in North America and China to Catalyst Pharmaceuticals, Inc. and Sperogenix Therapeutics, respectively. The company recently secured a Fr.69.00M post-IPO debt investment on 18 June 2024, with funding from Highbridge Capital Management and R-Bridge. With a focus on biotechnology and pharmaceuticals, Santhera Pharmaceuticals remains committed to addressing unmet medical needs in the healthcare industry. For more information, please visit the Company's website at www.santhera.com.